Discovery of Novel Imidazopyridine GSK-3β Inhibitors Supported by Computational Approaches
- PMID: 32380735
- PMCID: PMC7248956
- DOI: 10.3390/molecules25092163
Discovery of Novel Imidazopyridine GSK-3β Inhibitors Supported by Computational Approaches
Abstract
The interest of research groups and pharmaceutical companies to discover novel GSK-3β inhibitors has increased over the years considering the involvement of this enzyme in many pathophysiological processes and diseases. Along this line, we recently reported on 1H-indazole-3-carboxamide (INDZ) derivatives 1-6, showing good GSK-3β inhibition activity. However, they suffered from generally poor central nervous system (CNS) permeability. Here, we describe the design, synthesis, and in vitro characterization of novel imidazo[1,5-a]pyridine-1-carboxamide (IMID 1) and imidazo[1,5-a]pyridine-3-carboxamide (IMID 2) compounds (7-18) to overcome such liability. In detail, structure-based approaches and fine-tuning of physicochemical properties guided the design of derivatives 7-18 resulting in ameliorated absorption, distribution, metabolism, and excretion (ADME) properties. A crystal structure of 16 in complex with GSK-3β enzyme (PDB entry 6Y9S) confirmed the in silico models. Despite the nanomolar inhibition activity, the new core compounds showed a reduction in potency with respect to INDZ derivatives 1-6. In this context, Molecular Dynamics (MD) and Quantum Mechanics (QM) based approaches along with NMR investigation helped to rationalize the observed structure activity relationship (SAR). With these findings, the key role of the acidic hydrogen of the central core for a tight interaction within the ATP pocket of the enzyme reflecting in good GSK-3β affinity was demonstrated.
Keywords: 1H-indazole-3-carboxamide core (INDZ); CNS permeability; NMR characterization; X-ray crystallography; glycogen synthase kinase-3β (GSK-3β); imidazo[1,5-a]pyridine-1-carboxamide core (IMID 1); imidazo[1,5-a]pyridine-3-carboxamide core (IMID 2); molecular docking; molecular dynamics (MD); quantum mechanics (QM).
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.Biomed Pharmacother. 2020 Aug;128:110249. doi: 10.1016/j.biopha.2020.110249. Epub 2020 May 26. Biomed Pharmacother. 2020. PMID: 32470749
-
Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors.J Mol Model. 2019 May 25;25(6):171. doi: 10.1007/s00894-019-4032-5. J Mol Model. 2019. PMID: 31129879
-
Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β.J Biomol Struct Dyn. 2019 Feb;37(2):275-290. doi: 10.1080/07391102.2018.1426043. Epub 2018 Jan 19. J Biomol Struct Dyn. 2019. PMID: 29310523
-
Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review.Eur J Med Chem. 2019 Feb 15;164:448-470. doi: 10.1016/j.ejmech.2018.12.073. Epub 2018 Dec 31. Eur J Med Chem. 2019. PMID: 30616053 Review.
-
Pharmacological Potential and Synthetic Approaches of Imidazo[4,5-b]pyridine and Imidazo[4,5-c]pyridine Derivatives.Molecules. 2017 Mar 4;22(3):399. doi: 10.3390/molecules22030399. Molecules. 2017. PMID: 28273868 Free PMC article. Review.
Cited by
-
Pinpointing top inhibitors for GSK3β from pool of indirubin derivatives using rigorous computational workflow and their validation using molecular dynamics (MD) simulations.Sci Rep. 2024 Jan 2;14(1):49. doi: 10.1038/s41598-023-50992-7. Sci Rep. 2024. PMID: 38168595 Free PMC article.
-
Molecular docking, molecular dynamics simulations and in vitro screening reveal cefixime and ceftriaxone as GSK3β covalent inhibitors.RSC Adv. 2023 Apr 11;13(17):11278-11290. doi: 10.1039/d3ra01145c. eCollection 2023 Apr 11. RSC Adv. 2023. PMID: 37057264 Free PMC article.
-
BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies.Int J Mol Sci. 2023 Feb 3;24(3):3008. doi: 10.3390/ijms24033008. Int J Mol Sci. 2023. PMID: 36769327 Free PMC article.
-
Differential Interactome Based Drug Repositioning Unraveled Abacavir, Exemestane, Nortriptyline Hydrochloride, and Tolcapone as Potential Therapeutics for Colorectal Cancers.Front Bioinform. 2021 Sep 14;1:710591. doi: 10.3389/fbinf.2021.710591. eCollection 2021. Front Bioinform. 2021. PMID: 36303724 Free PMC article.
-
Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward.Front Mol Neurosci. 2022 Jan 21;14:792364. doi: 10.3389/fnmol.2021.792364. eCollection 2021. Front Mol Neurosci. 2022. PMID: 35126052 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
